REFERENCES
- Bernichtein S, Touraine P, Goffin V. New concepts in prolactin biology. J Endocrinol. 2010;206:1–11.
- Verhelst J, Abs R. Hyperprolactinemia: Pathophysiology and management. Treat Endocrinol. 2003;2(1):23–32.
- Hou SH, Grossman S, Molitch ME. Hyperprolactinemia in patients with renal insufficiency and chronic renal failure requiring hemodialysis or chronic ambulatory peritoneal dialysis. Am J Kidney Dis. 1985;6(4):245–249.
- Schaefer F. Endocrine and growth disorders in chronic kidney disease. In: Avner ED, Harmon WE, Niaudet P, Yoshikawa N, eds. Pediatric Nephrology. 6th ed. Berlin: Springer; 2009:1713–1753.
- Steiner J, Cassar J, Mashiter K, Dawes I, Fraser TR, Breckenridge A. Effect of methyldopa on prolactin and growth hormone. Br Med J. 1976;1(6019):1186–1188.
- Ramirez G, O’Neill WM, Bloomer HA, Jubiz W. Abnormalities in the regulation of prolactin in patients with chronic renal failure. J Clin Endocrinol Metab. 1977;45(4):658–661.
- Kolloch R, Kobayashi K, Dequattro V. Dopaminergic control of sympathetic tone and blood pressure: Evidence in primary hypertension. Hypertension. 1980;2(4):390–394.
- Dos Santos Nunes V, El Dib R, Boquszewski CL, Nogueira CR. Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: A systematic review of randomized controlled trials and meta-analysis. Pituitary. 2011;14(3): 259–265.